NBIX icon

Neurocrine Biosciences

267 hedge funds and large institutions have $7.29B invested in Neurocrine Biosciences in 2017 Q4 according to their latest regulatory filings, with 65 funds opening new positions, 82 increasing their positions, 93 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more capital invested

Capital invested by funds: $ → $

more funds holding

Funds holding:

more funds holding in top 10

Funds holding in top 10:

2.62% less ownership

Funds ownership: 108.79%106.18% (-2.6%)

12% less repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 93

22% less call options, than puts

Call options by funds: $30.8M | Put options by funds: $39.6M

Holders
267
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
7
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$30.8M
Puts
$39.6M
Net Calls
Net Calls Change

Top Buyers

1 +$75.2M
2 +$35.3M
3 +$32.4M
4
BBA
Baker Bros. Advisors
New York
+$30.1M
5
Renaissance Technologies
Renaissance Technologies
New York
+$30M

Top Sellers

1 -$75.8M
2 -$43.6M
3 -$42.4M
4
Deutsche Bank
Deutsche Bank
Germany
-$37.3M
5
State Street
State Street
Massachusetts
-$36.4M
Name Holding Trade Value Shares
Change
Change in
Stake
1
$1.03B
2
$553M
3
$483M
4
$448M
5
$400M
6
$371M
7
$268M
8
$244M
9
$238M
10
$211M
11
$184M
12
$166M
13
$154M
14
$118M
15
$115M
16
$102M
17
$87M
18
$77.9M
19
$75.1M
20
$74.9M
21
$73.7M
22
$68M
23
$66.2M
24
$62.5M
25
$61.9M